Biohaven Q4 2022 net loss $201.1M; licenses TYK2/JAK1 inhibitor BHV-8000

Biohaven Ltd.

Q4 2022 net loss $201.1M ($3.32/share); cash $465.3M at year-end, no debt.
Acquired exclusive global ex-China rights to oral brain-penetrant TYK2/JAK1 inhibitor BHV-8000; Phase 1 start planned in 2023.
Completed Phase 1 SAD/MAD for Kv7 activator BHV-7000; no sedation/dizziness/ataxia; plans EEG study H1 2023 and pivotal H2 2023.
Appointed Bruce Car (CSO), Irfan Qureshi (CMO), Tanya Fischer (CDO) to management team.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Biohaven Ltd. reported financial results for fourth quarter and full year ended December 31, 2022.

Period: fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 23, 2023, Biohaven Ltd. (the " Registrant ") issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Biohaven Ltd. filing history →

Source: SEC EDGAR

accession 0001935979-23-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.